Drug Profile
Research programme: T-cell activated therapeutics - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center
Alternative Names: Allogeneic T-cell therapies - Atara/MSKCCLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 08 May 2018 Atara Biotherapeutics expands T-Cell immunotherapy collaboration to advance next-generation CAR T technologies in oncology, autoimmune and other diseases